2026 Q3 Healthcare Market Report

Echo Partners’ Q3 report covers healthcare and life sciences fund closes, venture financings, strategic acquisitions, and public-market performance. Two transactions show why the terms matter when benchmarking a deal.

Angle Health announced a $600 million transaction comprising a $200 million Series C and a $400 million tender offer for existing shareholders. Only the Series C represented new capital for the business. In M&A, Lilly’s acquisition of AtaiBeckley closed at $6.75 per share in cash, with up to another $2.50 per share tied to clinical and regulatory milestones. For boards comparing offers, the timing of those milestones and who controls them matter alongside the headline price.

On the fund side, Frazier Life Sciences added more than $1.1 billion in commitments to its existing public biotech fund, which can also invest in later-stage private companies. Two smaller rounds show what investors were willing to fund next. Caspian Therapeutics raised $50 million to advance a diabetes program originated at Kura Oncology, with the financing expected to fund development through initial clinical proof of concept. Evvy’s $40 million Series B will support validation of new diagnostic and care models, starting with fertility.

Our takeaway for companies preparing to raise: identify the milestone that could change the next investor’s decision, then budget through that milestone, a potential delay, and the time it will take to raise again.